Preoperative Evaluation of Neurosurgical Patients

Author(s):  
Aditya Munshi ◽  
Geno Merli

All patients undergoing noncardiac surgery are exposed to a risk of adverse surgical, anesthesia, and medical complications. Unlike procedural risk, the medical risks are often modifiable, and therefore stratification of patient medical risk prior to surgery forms the basis of reducing postoperative morbidity, mortality, and length of hospital stay. Patients undergoing neurosurgical procedures pose several unique challenges and require special focus. This patient subgroup also carries a high risk for thrombotic events from immobilization and interruption of pharmacological prophylaxis. Cardiovascular events occurring in the postoperative period are the primary focus of risk assessment in noncardiac surgery, and this is also true for neurosurgical procedures, many of which are performed emergently or urgently. The authors discuss cardiovascular risk stratification based on a patient’s functional status, exercise capacity, and prior cardiac history. They review risk assessment scales to aid decision-making and how to select patients for further testing. Bleeding complications can be devastating and are of great concern in neurosurgery; the chapter discusses assessment of bleeding risk using an approach that combines basic laboratory testing with a thorough history and physical exam. The authors address the risk of thromboembolic events in neurosurgery patients and provide recommendations for preoperative assessment and postoperative prophylaxis. This chapter covers a broad approach from the point of view of a hospitalist physician evaluating a patient preoperatively, including a review of current guidelines, recommendations, and future directions on risk stratification for cardiac, thrombotic, and bleeding complications.

2021 ◽  
Vol 22 (1) ◽  
Author(s):  
Thomas Sonnweber ◽  
Eva-Maria Schneider ◽  
Manfred Nairz ◽  
Igor Theurl ◽  
Günter Weiss ◽  
...  

Abstract Background Risk stratification is essential to assess mortality risk and guide treatment in patients with precapillary pulmonary hypertension (PH). We herein compared the accuracy of different currently used PH risk stratification tools and evaluated the significance of particular risk parameters. Methods We conducted a retrospective longitudinal observational cohort study evaluating seven different risk assessment approaches according to the current PH guidelines. A comprehensive assessment including multi-parametric risk stratification was performed at baseline and 4 yearly follow-up time-points. Multi-step Cox hazard analysis was used to analyse and refine risk prediction. Results Various available risk models effectively predicted mortality in patients with precapillary pulmonary hypertension. Right-heart catheter parameters were not essential for risk prediction. Contrary, non-invasive follow-up re-evaluations significantly improved the accuracy of risk estimations. A lack of accuracy of various risk models was found in the intermediate- and high-risk classes. For these patients, an additional evaluation step including assessment of age and right atrium area improved risk prediction significantly. Discussion Currently used abbreviated versions of the ESC/ERS risk assessment tool, as well as the REVEAL 2.0 and REVEAL Lite 2 based risk stratification, lack accuracy to predict mortality in intermediate- and high-risk precapillary pulmonary hypertension patients. An expanded non-invasive evaluation improves mortality risk prediction in these individuals.


2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Hamid Reza Marateb ◽  
Maja von Cube ◽  
Ramin Sami ◽  
Shaghayegh Haghjooy Javanmard ◽  
Marjan Mansourian ◽  
...  

Abstract Background Already at hospital admission, clinicians require simple tools to identify hospitalized COVID-19 patients at high risk of mortality. Such tools can significantly improve resource allocation and patient management within hospitals. From the statistical point of view, extended time-to-event models are required to account for competing risks (discharge from hospital) and censoring so that active cases can also contribute to the analysis. Methods We used the hospital-based open Khorshid COVID Cohort (KCC) study with 630 COVID-19 patients from Isfahan, Iran. Competing risk methods are used to develop a death risk chart based on the following variables, which can simply be measured at hospital admission: sex, age, hypertension, oxygen saturation, and Charlson Comorbidity Index. The area under the receiver operator curve was used to assess accuracy concerning discrimination between patients discharged alive and dead. Results Cause-specific hazard regression models show that these baseline variables are associated with both death, and discharge hazards. The risk chart reflects the combined results of the two cause-specific hazard regression models. The proposed risk assessment method had a very good accuracy (AUC = 0.872 [CI 95%: 0.835–0.910]). Conclusions This study aims to improve and validate a personalized mortality risk calculator based on hospitalized COVID-19 patients. The risk assessment of patient mortality provides physicians with additional guidance for making tough decisions.


2017 ◽  
Vol 30 (10) ◽  
pp. 1433-1442 ◽  
Author(s):  
Elizabeth G Demicco ◽  
Michael J Wagner ◽  
Robert G Maki ◽  
Vishal Gupta ◽  
Ilya Iofin ◽  
...  

2018 ◽  
Vol 6 (1) ◽  
pp. 63-74
Author(s):  
María Guadalupe Martino ◽  
Christian Müller

Abstract The civil economy approach is an attempt to reconcile economic market interactions with the normative standards of traditional virtue ethics. We analyze critically some of its main elements with a special focus on the concept of reciprocity, which plays a central role in the whole approach. Its strengths include, among others, virtue orientation, emphasis on happiness rather than utility, and in particular the notion of reciprocity. However, we argue that this concept of reciprocity would on average not be incentive compatible, and from a methodological point of view, the implied hypothesis of a homo reciprocans is not a viable alternative to the standard model of homo oeconomicus. We also consider that the approach is not entirely new, as it shares many characteristics with the social market economy conception.


Biomolecules ◽  
2018 ◽  
Vol 8 (3) ◽  
pp. 58 ◽  
Author(s):  
Evaldas Girdauskas ◽  
Johannes Petersen ◽  
Niklas Neumann ◽  
Shiho Naito ◽  
Tatiana Gross ◽  
...  

Bicuspid aortic valve (BAV) disease is the most common congenital malformation of the human heart with a prevalence of 1–2% in the general population. More than half of patients with a BAV present with a dilated proximal aorta (so-called bicuspid aortopathy) which is associated with an enhanced risk of life-threatening aortic complications. Up to now, the pathogenesis of bicuspid aortopathy as well as the risk stratification of aortic complications has not yet been sufficiently clarified. Recent findings have shown that bicuspid aortopathy features phenotypic heterogeneity. Two distinct valvulo-aortic phenotypes, the so-called root phenotype, as well as a dilation of the tubular ascending aorta, coincide with a significantly different risk for aortal complications. However, the phenotype-based classification that is only based on these two clinical forms is not sufficient to estimate the risk of aortal complications in a prognostically relevant way. Therefore, there is growing clinical interest to assess novel approaches in BAV research and to introduce circulating biomarkers as an elegant diagnostic tool to improve risk stratification in BAV aortopathy. A large scale epidemiological cohort study, ranking from apparently healthy individuals to disease patients, and comprehensive biobanks provide the opportunity to study BAV disease and its complications and to identify novel biomarkers for BAV aortopathy surveillance and prognosis. Firstly, the data indicate that several protein-based biomarkers and non-coding RNA molecules, in particular circulating microRNAs, can serve as relevant molecular biomarkers to predict the course of BAV-associated aortopathy. Here, we review the current literature and knowledge about BAV from a clinical point of view, and report about novel approaches in BAV biomarker research.


Sign in / Sign up

Export Citation Format

Share Document